

**Rowan University
Institutional Biosafety Committee (IBC) Meeting Minutes**

Meeting Date: June 5, 2025
Meeting Time: 10:13 AM – 11:41 AM
Meeting Location: Microsoft Teams
Chair: Dr. Kevin Currie

Voting Members:

Member	Role/Expertise	Present	Excused
Dr. E.C.	Chair	x	
Dr. L.P.	Scientist	x	
Dr. B.W.	Scientist	x	
Dr. C.K.	Scientist	x	
Dr. M.F.	Plant Expert	x	
Dr. E.M.	Animal Expert	x	
Mr. E.G.	Research Compliance Director	x	
Mr. T.B.	Biological Safety Officer	x	
Mr. S.G.	Non-affiliated	x	
Mr. R.H.	Non-affiliated		x

Guests: Ms. S.S. (Notetaker)

Quorum: The committee has ten voting members, and nine members were present.

- I. Call to Order and Conflicts of Interest
The IBC Chair called the meeting to order at 10:13 AM and reminded all members present to identify any conflicts of interest as each registration is reviewed.
- II. Review and approval of agenda
The June 5, 2025, agenda was approved unanimously.
- III. Review and approval of prior meeting minutes
Motion: Approve the April 3, 2025, and May 8, 2025, meeting minutes as written.
Votes: 9 For, 0 Against, 0 Abstain
- IV. Review of Prior Business
 - A. The conditions of the following registrations were verified and met for approval:
 1. Carabetta Lab, Personnel Amendment Approved 6/4/25
 2. Henry Lab, Personnel Amendment Approved 6/5/25

- V. Institutional Review Entity (IRE) - The Institutional Dual Use Research Contact (IDURC) did not receive any notifications about dual use concerns nor received any contact from researchers using select agents/toxins.
- VI. Chairman's Report - Reminder that the June meeting minutes once approved will be posted on the Rowan IBC public facing webpage.
- VII. Biological Safety Officer (BSO) / Environmental Health & Safety (EH&S) Report
 - A. No issues of concern were raised. Personnel training and lab inspection report was summarized by BSO.
- VIII. New Business

Mr. S.G. recused at 11:00 AM

- A. Pandey Lab Biological Registration - Renewal
 - a. **PI:** Manoj Pandey
 - b. **Project Title and #:** Development of Novel BTK inhibitor, #67
 - c. **NIH Sponsored:** Yes
 - d. **Summary:** The project aims to treat multiple myeloma (MM) by blocking two important parts of the cancer cells at the same time: a protein called BTK, which helps the cells grow and survive and microtubules which are structures inside cells that help them divide and move. Both of these targets are essential for cancer cells to function, but no one has yet tried to block them together in MM.
 - e. **Risk Assessment:** Biosafety Level 2; Animal Biosafety Level 2
 - f. **Personnel Training:** Required laboratory personnel training is not completed for all individuals: General Laboratory, Biological Laboratory, r/sDNA, and Hazardous Biological.
 - g. **NIH Guidelines Sections for Research with Recombinant or Synthetic Nucleic Acid Molecules:** III-F-1,2,3
 - h. **Committee Deliberation and Motion:** Clarifications and modifications are required with full committee review:
 - i. Clarify use of face mask or respirator, include safety eyewear
 - ii. Describe disposal of bortezomib solutions, state whether an appropriate spill kit is available for cytotoxic drugs, name cleaning agent used for decontamination.
 - iii. Clarify whether the [REDACTED] xenograft model is used or not.
 - iv. In the Brief Summary and Description of Experimental Details indicate BSL2 for human cell line use
 - v. Identify [REDACTED] locations in Rooms and Spaces
 - vi. In the r/s DNA survey under 7Di, remove X under "Transgenic Arthropods"
 - vii. Clarify "All procedures involving the isolation of multiple myeloma cells from bone marrow aspirates or the use of any primary patient-derived MM cells" whether IRB approved.
 - viii. The recorded plasmid is listed as pCMV-GCaMP5G which encodes a calcium sensor. It seems this was made in error as no calcium sensing was described in this protocol. Further, this is at odds with Step 3 which lists the insert as "BTK". Significant revision is required. Please correct the vector details and provide the specific purpose and experimental use of the lentiviral vector, presumably expressing BTK. If cells will be transduced

for functional studies, indicate which cell types are involved, what experiments they will be used in, and whether they will be used in [REDACTED]. Also confirm that all lentiviral handling and transduction procedures will occur under BSL-2 conditions, consistent with NIH Guidelines.

ix. Training of personnel not experienced with BSL2 is required.

Vote: 8 in favor, 0 opposed, 0 abstained

IX. For the Good of the Committee 11:18 AM

X. Meeting Adjournment: The IBC Chair moved to adjourn the meeting 11:41 AM.